Michael Anthony O'Rorke

Dr. Michael Anthony O'Rorke

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
EMEsther Molina-Montes
Esther Molina-Montes
LHLisa Van Hoogstraten
Lisa Van Hoogstraten
PGPaulina Gomez-Rubio
Paulina Gomez-Rubio
MLMatthias Löhr
Matthias Löhr
LSLinda Sharp
Linda Sharp
NMNuria Malats
Nuria Malats
Background: Despite smoking being a well-established risk factor for pancreatic cancer, there is a need to further characterize pancreatic cancer risk according to lifespan smoking patterns and other smoking features, such as tobacco type. Our aim was to deeply investigate them within a large European case–control study.Methods: Tobacco smoking habits and other relevant information were obtained from 2,009 cases and 1,532 controls recruited in the PanGenEU study using standardized tools. Multivariate logistic regression analysis was performed to evaluate pancreatic cancer risk by smoking characteristics and interactions with other pancreatic cancer risk factors. Fractional polynomials and restricted cubic splines were used to test for nonlinearity of the dose–response relationships and to analyze their shape.Results: Relative to never-smokers, current smokers [OR = 1.72; 95% confidence interval (95% CI), 1.39–2.12], those inhaling into the throat (OR = 1.48; 95% CI, 1.11–1.99) or chest (OR = 1.33; 95% CI, 1.12–1.58), and those using nonfiltered cigarettes (OR = 1.69; 95% CI, 1.10–2.61), were all at an increased pancreatic cancer risk. Pancreatic cancer risk was highest in current black tobacco smokers (OR = 2.09; 95% CI, 1.31–3.41), followed by blond tobacco smokers (OR = 1.43; 95% CI, 1.01–2.04). Childhood exposure to tobacco smoke relative to parental smoking was also associated with increased pancreatic cancer risk (OR = 1.24; 95% CI, 1.03–1.49). Dose–response relationships for smoking duration, intensity, cumulative dose, and smoking cessation were nonlinear and showed different shapes by tobacco type. Effect modification by family history of pancreatic cancer and diabetes was likely.Conclusions: This study reveals differences in pancreatic cancer risk by tobacco type and other habit characteristics, as well as nonlinear risk associations.Impact: This characterization of smoking-related pancreatic cancer risk profiles may help in defining pancreatic cancer high-risk populations.

6 December 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
EHEmma Herbach
Emma Herbach
MOMichael Anthony O'Rorke
Michael Anthony O'Rorke
RCRyan M. Carnahan
Ryan M. Carnahan
BMBradley D. McDowell
Bradley D. McDowell
BABryan Allen
Bryan Allen
ECElizabeth Chrischilles
Elizabeth Chrischilles
Background: We compared cardiac outcomes for surgery‐eligible patients with stage III non‐small‐cell lung cancer treated adjuvantly or neoadjuvantly with chemotherapy versus chemo‐radiation therapy in the Surveillance, Epidemiology and End Results‐Medicare database. Methods and Results: Patients were age 66+, had stage IIIA/B resectable non‐small‐cell lung cancer diagnosed between 2007 and 2015, and received adjuvant or neoadjuvant chemotherapy or chemo‐radiation within 121 days of diagnosis. Patients having chemo‐radiation and chemotherapy only were propensity‐score matched and followed from day 121 to first cardiac outcome, noncardiac death, radiation initiation by patients who received chemotherapy only, fee‐for‐service enrollment interruption, or December 31, 2016. Cause‐specific hazard ratios (HRs) and competing risks subdistribution HRs were estimated. The primary outcome was the first of these severe cardiac events: acute myocardial infarction, other hospitalized ischemic heart disease, hospitalized heart failure, percutaneous coronary intervention/coronary artery bypass graft, cardiac death, or urgent/inpatient care for pericardial disease, conduction abnormality, valve disorder, or ischemic heart disease. With median follow‐up of 13 months, 70 of 682 patients who received chemo‐radiation (10.26%) and 43 of 682 matched patients who received chemotherapy only (6.30%) developed a severe cardiac event ( P =0.008) with median time to first event 5.45 months. Chemo‐radiation increased the rate of severe cardiac events (cause‐specific HR: 1.62 [95% CI, 1.11–2.37] and subdistribution HR: 1.41 [95% CI, 0.97–2.04]). Cancer severity appeared greater among patients who received chemo‐radiation (noncardiac death cause‐specific HR, 2.53 [95% CI, 1.93–3.33] and subdistribution HR, 2.52 [95% CI, 1.90–3.33]). Conclusions: Adding radiation therapy to chemotherapy is associated with an increased risk of severe cardiac events among patients with resectable stage III non‐small‐cell lung cancer for whom survival benefit of radiation therapy is unclear.

3 June 2025 in JMIR Human Factors
Verified
Journal Article
Open access
JHJuan Pablo Hourcade
Juan Pablo Hourcade
MOMichael Anthony O'Rorke
Michael Anthony O'Rorke
ECElizabeth Chrischilles
Elizabeth Chrischilles
NRNicholas J Rudzianski
Nicholas J Rudzianski
BGBrian Gryzlak
Brian Gryzlak
MWMaryann Wahmann
Maryann Wahmann
Background: Personal health record (PHR) software has the potential of aiding with patient engagement and data collection in longitudinal research to better understand the long-term impact of treatments on patients with rare medical conditions. Neuroendocrine tumors (NETs) represent a rare condition with unique challenges related to symptom management, treatment tracking, and patient-provider communication. Objective: This study aimed to design, develop, and evaluate PHR software tailored for patients with NETs as part of a longitudinal research study. Our goal was to create a patient-centered PHR that supports both self-management and research data collection. Methods: This included activities spanning the entire development lifecycle from identifying user requirements through focus groups and surveys, iterative prototype refinement via cognitive walkthroughs, and usability testing of the functional PHR system. Feedback from patient advocacy organizations and clinical experts further informed PHR development. Results: The resulting PHR allows patients with NETs to access condition-specific information, track symptoms, monitor treatment regimens, and share data with health care providers. Patients valued the ability to visualize personal health trends and patterns over time, enhancing both self-management and communication with medical teams. Usability testing indicated high levels of patient satisfaction with the system’s functionality and design. Conclusions: The development of this PHR demonstrates the value of engaging patients in the design process to ensure that health technologies address real-world needs. Our approach provides a model for designing PHR systems for other rare conditions, highlighting the importance of patient-centered design in supporting both clinical care and longitudinal research.

2 November 2024 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Open access
PDF file
TXTao Xu
Tao Xu
JDJoseph S. Dillon
Joseph S. Dillon
MMMary A. Maluccio
Mary A. Maluccio
DQDawn E. Quelle
Dawn E. Quelle
SNSarah H. Nash
Sarah H. Nash
MOMichael Anthony O'Rorke
Michael Anthony O'Rorke
Purpose: Renal and hematological toxicity are side effects and dose-limiting factors of Peptide Receptor Radionuclide Therapy (PRRT). We aimed to assess the changes in renal and hematological function and associations with survival in neuroendocrine tumor (NET) patients treated with PRRT. Methods: A retrospective cohort of 448 NET patients treated with either 177Lu-DOTATATE or 90Y-DOTATOC were followed for changes of renal and hematological function. Renal function was assessed by monitoring changes in serum creatinine, blood urea nitrogen and estimated glomerular filtration rate. Hematological function was determined by examining changes in white blood cell counts (WBC), platelet counts, and hemoglobin levels over time. Piecewise linear mixed effect models were applied to model the longitudinal repeated measurements of renal and hematological function. Overall survival (OS) and progression-free survival (PFS) were modelled using Cox proportional hazard regressions. Results: Of the 448 PRRT treated patients, 335 received 177Lu-DOTATATE (74.78%) and 113 were treated with 90Y-DOTATOC (25.22%). Comparing patients treated with 177Lu-DOTATATE to those treated with 90Y-DOTATOC, renal function did not differ significantly prior to, during or after PRRT. Compared with patients treated with 90Y-DOTATOC, significantly decreased indicators of hematological function were observed in those treated with 177Lu-DOTATATE prior to and during PRRT treatment (WBC: estimate, -0.10, 95% CI, -0.15 to -0.05; P < 0.001; platelet count: estimate, -2.53, 95% CI, -3.83 to -1.24; P < 0.001), and no significant recovery was observed in hematological function post PRRT. Individuals who received 177Lu-DOTATATE tended to have a longer PFS (hazard ratio, 0.47, 95%CI: 0.28–0.79, P = 0.004) compared with 90Y-DOTATOC, but there was no difference in OS. Conclusion: There was no significant renal, but minor hematological toxicity, in patients treated with 177Lu-DOTATATE compared with 90Y-DOTATOC. Compared to 90Y-DOTATOC, 177Lu-DOTATATE appears to enhance PFS, but not OS. Treatment with 177Lu-DOTATATE may necessitate follow-up for hematological toxicity irrespective of other therapies prior to PRRT.

1 December 2024 in JCO Clinical Cancer Informatics
Verified
Journal Article
Closed access
BMBradley D. McDowell
Bradley D. McDowell
MOMichael Anthony O'Rorke
Michael Anthony O'Rorke
MSMary Chen Schroeder
Mary Chen Schroeder
ECElizabeth Chrischilles
Elizabeth Chrischilles
CSChristine Spinka
Christine Spinka
JVJeffrey J. VanWormer
Jeffrey J. VanWormer
PURPOSE: Electronic health records (EHRs) comprise a rich source of real-world data for cancer studies, but they often lack critical structured data elements such as diagnosis date and disease stage. Fortunately, such concepts are available from hospital cancer registries. We describe experiences from integrating cancer registry data with EHR and billing data in an interoperable data model across a multisite clinical research network. METHODS: After sites implemented cancer registry data into a tumor table compatible with the PCORnet Common Data Model (CDM), distributed queries were performed to assess quality issues. After remediation of quality issues, another query produced descriptive frequencies of cancer types and demographic characteristics. This included linked BMI. We also report two current use cases of the new resource. RESULTS: Eleven sites implemented the tumor table, yielding a resource with data for 572,902 tumors. Institutional and technical barriers were surmounted to accomplish this. Variations in racial and ethnic distributions across the sites were observed; the percent of tumors among Black patients ranged from <1% to 15% across sites, and the percent of tumors among Hispanic patients ranged from 1% to 46% across sites. Current use cases include a pragmatic prospective cohort study of a rare cancer and a retrospective cohort study leveraging body size and chemotherapy dosing. CONCLUSION: Integrating cancer registry data with the PCORnet CDM across multiple institutions creates a powerful resource for cancer studies. It provides a wider array of structured, cancer-relevant concepts, and it allows investigators to examine variability in those concepts across many treatment environments. Having the CDM tumor table in place enhances the impact of the network's effectiveness for real-world cancer research.

21 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
AAAbdallah Attia
Abdallah Attia
JHJihun Hamm
Jihun Hamm
MAMahmoud A. AbdAlnaeem
Mahmoud A. AbdAlnaeem
Zhengming DingZhengming Ding
Zhengming Ding
MOMichael Anthony O'Rorke
Michael Anthony O'Rorke
KLKristen E. Limbach
Kristen E. Limbach
Background. Preoperative risk stratification of pancreatic neuroendocrine tumors (PNETs) is constrained by the unavailability of histologic grade before resection. We hypothesized that a panel of biologically informed CT-radiomic signatures, combined with patient-level Δ-radiomics referenced to the contralateral pancreas, would support preoperative discrimination of progression and grade in a two-center pilot cohort. Methods. Forty-four patients with histologically confirmed PNET who underwent contrast-enhanced preoperative CT and surgical resection at two academic centers were analyzed. Lesion and contralateral non-tumor-bearing pancreatic parenchyma regions of interest were revised in 3D Slicer by a board-certified pancreatic surgeon and verified intraoperatively against surgical pathology. PyRadiomics v3.0 features were extracted with IBSI-concordant settings. Parametric ComBat batch correction was applied across the two centers (biological-covariate balance verified beforehand), and Δ-radiomic features (lesion combat–pancreas combat) were computed for the 106 intensity/texture primitives. We constructed a panel of biology-informed hybrid signatures partitioned into a preoperative lesion-only family (Family A; seven signatures) and a preoperative Δ-radiomic family (Family B; three signatures). Candidate features were filtered through correlation clustering, baseline-adjusted likelihood-ratio testing with Benjamini–Hochberg FDR control, and 100-bootstrap stability selection. Three predictor blocks were compared per target with three classifiers each (Logistic Regression, Random Forest, Gradient Boosting): M0 (five-variable clinical baseline), MA (M0 + Family A), and MB (M0 + Family B). Discrimination was reported as AUC with bootstrap 95% CI; calibration was assessed using the Brier score and TRIPOD-recommended calibration intercept and slope; and cross-center generalization was evaluated with leave-one-center-out (LOCO) cross-validation. Univariable Cox regression with bootstrap and permutation inference was used for progression-free survival (PFS). Results. The cohort had 16 progression events and eight deaths (median follow-up was 38 months, IQR 14–59). Prespecified clinical–radiomic and Δ-radiomic signatures were associated with progression-free survival, including B2 = ΔBusyness × Ki-67 (HR 0.38, 95% CI 0.19–0.76, p = 0.006). For progression prediction, the Δ-radiomic model achieved the strongest discrimination, with a nested cross-validation AUC of 0.85 and leave-one-center-out AUC of 0.87. For higher-grade disease, radiomic models also demonstrated high discrimination, with AUCs up to 0.93. Conclusions. Radiomics-derived shape and texture features, especially when combined with clinical markers, may noninvasively identify aggressive PNET phenotypes and support preoperative risk stratification. Prospective validation in larger multicenter cohorts is warranted.